ORTHOUNION

Project ID: 733288
Funded under: H2020-EU.3.1.3. - Treating and managing disease

ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONS

From 2017-01-01 to 2021-12-31, ongoing project

Project details

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>Topic(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 5 999 150,87</td>
<td>SC1-PM-11-2016-2017 - Clinical research on regenerative medicine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EU contribution:</th>
<th>Call for proposal:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 5 999 150,87</td>
<td>H2020-SC1-2016-RTD See other projects for this call</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coordinated in:</th>
<th>Funding scheme:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spain</td>
<td>RIA - Research and Innovation action</td>
</tr>
</tbody>
</table>

Objective

Current orthopaedic treatments permit spontaneous bone regeneration to unite and heal 90% bone injuries. Non-union associates pain and disability, often requiring biological enhancement. Regenerative medicine research suggests to the general public that alternative treatments based on advanced therapy medicinal products (ATMP) are already available. However, early clinical trials only explore its potential benefit. Underreported results and absence of early trial confirmation in adequately powered prospective randomized clinical trials (RCT) indicate that evidence is not available to transfer any technique into routine clinical application.

This ORTHOUNION Project was developed from FP7-Project (REBORNE). Its results confirmed 92% bone healing rate (Gómez-Barrena et al, 2016 submitted manuscript) with an autologous ATMP of GMP expanded bone marrow derived human MSC in non-unions, where the reported bone healing rate after surgery with standard bone autograft is 74%. Any further development requires adequately powered prospective randomized clinical trials (RCT) indicate that evidence is not available to transfer any technique into routine clinical application.

This ORTHOUNION Project was developed from FP7-Project (REBORNE). Its results confirmed 92% bone healing rate (Gómez-Barrena et al, 2016 submitted manuscript) with an autologous ATMP of GMP expanded bone marrow derived human MSC in non-unions, where the reported bone healing rate after surgery with standard bone autograft is 74%. Any further development requires adequately powered prospective randomized clinical trials (RCT). This will be the main aim of ORTHOUNION: to assess clinically relevant efficacy of an autologous ATMP with GMP multicentric production in a well-designed, randomized, controlled, three-arm clinical trial under GCP, versus bone autograft, gold-standard in fracture non-unions. A non-inferiority analysis will evaluate if cell dose can be lowered. ATMP has been authorized by the National Competent Authorities of the participating countries in 3 previous trials (REBORNE) and will be monitored by ECRIN-ERIC to ensure quality and credibility of RCT results.

Secondary aims include innovative strategies to increase manufacturing capacity and lower costs to pave translation into routine clinical treatments, biomaterial refinement to facilitate surgery, personalized medicine supportive instruments for patient selection and monitoring, and health economic evaluation. Results in this project may help define the future of bone regenerative medicin

Related information

News
Growing new bone for more effective injury repair
Coordinator

UNIVERSIDAD AUTONOMA DE MADRID
CALLE EINSTEIN 3 CIUDAD UNIV CANTOBLANCO RECTORADO
28049 MADRID
Spain

**EU contribution:** EUR 824 210,01

See on map

Activity type: Higher or Secondary Education Establishments

Contact the organisation

Participants

SERVICIO MADRILENO DE SALUD
PLAZA CARLOS TRIAS BERTRAN 7
28020 MADRID
Spain

**EU contribution:** EUR 1 352 056

See on map

Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

Contact the organisation

ETABLISSEMENT FRANCAIS DU SANG
AVENUE DU STADE DE FRANCE 20
93210 LA PLAINE SAINT DENIS
France

**EU contribution:** EUR 394 743,25

See on map

Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

Contact the organisation

UNIVERSITAET ULM
HELMHOLTZSTRASSE 16
89081 ULM
Germany

**EU contribution:** EUR 998 476,63

See on map

Activity type: Higher or Secondary Education Establishments

Contact the organisation

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
RUE DE TOLBIAC 101
75654 PARIS
France

**EU contribution:** EUR 221 230

See on map

Activity type: Research Organisations

Contact the organisation
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
5 RUE WATT
75013 PARIS
France
EU contribution: EUR 573 694

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS
BOULEVARD TONELLE 2
37044 TOURS CEDEX 9
France
EU contribution: EUR 193 125

ISTITUTO ORTOPEDICO RIZZOLI
VIA DI BARBIANO 1/10
40136 BOLOGNA
Italy
EU contribution: EUR 449 923,48

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
VIA UNIVERSITA 4
41121 MODENA
Italy
EU contribution: EUR 293 680

FONDAZIONE IRCCS CA’ GRANDA - OSPEDALE MAGGIORE POLICLINICO
VIA FRANCESCO SFORZA 28
20122 MILANO
Italy
EU contribution: EUR 420 950

Activity type: Research Organisations
Contact the organisation

Activity type: Higher or Secondary Education Establishments
Contact the organisation
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Last updated on 2017-07-24
Retrieved on 2018-11-17

© European Union, 2018